What we're anticipating at JPM 2024

There’s no shortage of predicting and trendspotting in healthcare this time of year. But as always, we’re taking a more analytical approach. Leveraging our proprietary Real Chemistry AI technology and trends monitoring, my Integrated Intelligence colleagues and I predicted the top trends we expect to shape the most significant conversations at this week’s J.P. Morgan Healthcare Conference. Our take: 2023 set the stage for the trends that will activate strategies in 2024, but if 2023 was all about possibility and potential, this year will be defined by action and results.?

Agree? Disagree? Leave a comment with your take about these trends or others that you think will pop up during the conference.??

AI moves from buzzword to building block.?

AI continues to be a buzzword across industries, but in healthcare, it’s increasingly being put into action: Its latest applications range from AI-powered diagnostic tools to the integration of generative AI in healthcare IT systems. While AI will certainly not solve all of healthcare’s current ills, innovators will almost certainly deploy it in ways that can meaningfully address some of the industry’s biggest challenges – from R&D to value-based care delivery.

At JPM 2024, we can expect to hear about the shift toward AI-first solutions and the integration of AI in legacy systems, with speakers spotlighting how they’re using AI to improve everything from their research pipelines to their bottom lines.?

?

Eyes are turning towards Eli Lilly & Novo Nordisk to predict the future of the obesity market.??

In 2023, Ozempic entered the mainstream vernacular as consumers unpacked the drug’s weight loss applications. Between public interest and a flurry of prominent medications,?we anticipate that the realities and ripple effects of transformative obesity care will be at this year’s conference – with both Novo Nordisk CEO, Lars Fruergaard J?rgensen, and Eli Lilly Chair and CEO, David A. Ricks speaking at the conference this week. Ricks may speak to the company’s recent launch of LillyDirect – a service that facilitates telehealth prescriptions for weight loss drugs, potentially broadening access to Lilly’s recently approved obesity medication, Zepbound. There’s no shortage of hype, but 2024 will likely be the year when we really start to see how the interplay among payers, providers, patients, pharma, retail, and tech will impact both health economics and health outcomes.? We’re excited to see how these obesity conversations?take?shape and what they mean for 2024 - and beyond.

??

Telehealth is poised for an exponential rise in 2024.?

Not only are we seeing recent telehealth expansions by major players such as Amazon and GNC Health, but notable public tech companies like Talkspace, Oscar, and Clover Health shared optimistic profitability projections for 2024. With growing consumer interest in virtual healthcare, and the potential of telehealth to address ongoing workforce shortages, telehealth may continue to be a growing area of interest. The rise of telehealth may have broader implications for healthcare companies beyond the telehealth sector changing consumer behavior across categories. Importantly, online pharmacies are jumping full force into the GLP-1 and obesity management market, as are health and wellness apps like Noom. Even tried and true weight loss industry companies, like Weight Watchers, are touting their telehealth access to GLP-1s. This shift can help move telehealth beyond just usage for routine virtual visits and urgent care needs.